- Home
- NVOS vs PSTV Comparison
NVOS vs PSTV Comparison
Compare NVOS & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVOS
- PSTV
- Stock Information
- Founded
- NVOS 2000
- PSTV 1996
- Country
- NVOS United States
- PSTV United States
- Employees
- NVOS N/A
- PSTV N/A
- Industry
- NVOS Assisted Living Services
- PSTV Medical/Dental Instruments
- Sector
- NVOS Health Care
- PSTV Health Care
- Exchange
- NVOS Nasdaq
- PSTV Nasdaq
- Market Cap
- NVOS 5.6M
- PSTV 9.4M
- IPO Year
- NVOS 2017
- PSTV N/A
- Fundamental
- Price
- NVOS $0.23
- PSTV $1.41
- Analyst Decision
- NVOS
- PSTV Strong Buy
- Analyst Count
- NVOS 0
- PSTV 2
- Target Price
- NVOS N/A
- PSTV $14.00
- AVG Volume (30 Days)
- NVOS 326.8K
- PSTV 84.6K
- Earning Date
- NVOS 12-12-2024
- PSTV 10-29-2024
- Dividend Yield
- NVOS N/A
- PSTV N/A
- EPS Growth
- NVOS N/A
- PSTV N/A
- EPS
- NVOS N/A
- PSTV N/A
- Revenue
- NVOS $13,516,958.00
- PSTV $5,509,000.00
- Revenue This Year
- NVOS N/A
- PSTV $11.13
- Revenue Next Year
- NVOS N/A
- PSTV N/A
- P/E Ratio
- NVOS N/A
- PSTV N/A
- Revenue Growth
- NVOS 1102.98
- PSTV 113.20
- 52 Week Low
- NVOS $0.20
- PSTV $0.97
- 52 Week High
- NVOS $3.45
- PSTV $2.78
- Technical
- Relative Strength Index (RSI)
- NVOS 38.13
- PSTV 46.79
- Support Level
- NVOS $0.20
- PSTV $1.20
- Resistance Level
- NVOS $0.31
- PSTV $1.45
- Average True Range (ATR)
- NVOS 0.03
- PSTV 0.10
- MACD
- NVOS 0.00
- PSTV 0.01
- Stochastic Oscillator
- NVOS 27.18
- PSTV 57.37
About NVOS Novo Integrated Sciences Inc.
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).